ANDRES MANUEL R
CERVANTES RUIPEREZ
CATEDRÁTICO/A DE UNIVERSIDAD
University Medical Center Utrecht
Utrecht, HolandaPublications in collaboration with researchers from University Medical Center Utrecht (6)
2024
-
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Nature Medicine, Vol. 30, Núm. 1, pp. 271-278
-
European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4)
European Journal of Cancer, Vol. 204
2023
-
Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe
European Journal of Cancer, Vol. 185, pp. 28-39
-
Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: A multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancer
European Journal of Surgical Oncology, Vol. 49, Núm. 1, pp. 21-28
2017
-
Phase Ib study of lumretuzumab plus cetuximab or erlotinib in solid tumor patients and evaluation of HER3 and heregulin as potential biomarkers of clinical activity
Clinical Cancer Research, Vol. 23, Núm. 18, pp. 5406-5415
2016
-
First-in-human phase i study of lumretuzumab, a glycoengineered humanized anti-HER3 monoclonal antibody, in patients with metastatic or advanced HER3-positive solid tumors
Clinical Cancer Research, Vol. 22, Núm. 4, pp. 877-885